)

Ligand Pharmaceuticals (LGND) investor relations material
Ligand Pharmaceuticals 16th Annual Midwest Ideas Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Business overview and strategy
Focuses on acquiring and investing in late-stage clinical and commercial biopharma programs to generate royalty revenue, with 12 major commercial royalty drivers expected to deliver $150M in revenue this year, up from $109M last year.
Operates two technology platforms, Captisol and Nitrocil, and maintains a pipeline of 90 partnered programs, emphasizing infrastructure-light, high-margin, and predictable growth.
Holds $245M in cash and investments, a $200M credit facility, and recently closed a $460M convertible note, providing $800M in deployable capital for annual investments of $150M–$250M.
Utilizes four main tactics for royalty acquisition: royalty monetization, project finance (synthetic royalties), special situations (including M&A and asset incubation), and platform technologies.
Team has deep investment and operational experience, with recent strategic leadership changes and a focus on scaling the royalty aggregation model.
Portfolio highlights and growth drivers
Portfolio is diversified across large pharma and mid-sized companies, with royalty rates ranging from low single digits to mid-teens.
Key growth drivers include Filspari (approved for IgA nephropathy, potential in FSGS), O2Ver (novel COPD treatment, strong launch, Merck acquisition pending), and Palvella’s Qtorin Rapamycin (potential first-in-class for rare skin diseases).
Filspari could generate $90M in annual royalties for each indication if approved, with important regulatory catalysts expected soon.
O2Ver’s peak sales estimates have risen to $3.5B, with potential to reach $6–7B under Merck, translating to $100M in annual royalties.
Palvella’s programs could yield $150M in royalties, with key clinical readouts expected by early next year.
Financial performance and outlook
Q2 revenue grew 15% to $47.6M, with royalties up 57% year-over-year; full-year revenue guidance raised to $200M–$225M and adjusted EPS to $6.70–$7.00.
Convertible note issuance provided favorable terms, further strengthening the balance sheet and supporting business development.
Major restructuring in 2022 included spinning out the antibody business and bringing in a new CEO, with a focus on high-growth, high-margin royalty investments.
Long-term outlook targets a 22% CAGR over five years, with commercial portfolio contributing 13% growth, late-stage pipeline 5%, and future investments 4%.
Recent product outperformance and new launches underpin upward revisions to guidance and future growth expectations.
Next Ligand Pharmaceuticals earnings date

Next Ligand Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage